Results 51 to 60 of about 313,407 (265)

Acute Myeloid Leukemia

Apollo Medicine, 2004
AbstractAdvances in our understanding of the pathophysiology of acute myeloid leukemia (AML) have not yet led to major improvements in disease-free and overall survival of adults with this disease. Only about one-third of those between ages 18–60 who are diagnosed with AML can be cured; disease-free survival is rare and current therapy devastating in ...
Richard M, Stone, Margaret R, O'Donnell, Mikkael A, Sekeres   +2 more
openaire   +3 more sources

The Future of Pediatric Hematology‐Oncology Fellowship Training: Reflections on the American Board of Pediatrics Training Model

Pediatric Blood &Cancer, EarlyView.
Scott C. Borinstein, Scott Moerdler, Alexander A. Boucher, Stacy L. Cooper, Rachel A Egler, Erika Friehling, Richard Ho, Catherine McGuinn, Kathryn S. Sutton, Stacey G. Zahler, Leslie Kersun, Jennifer Kesselheim   +11 more
wiley   +1 more source

On Hierarchical Composite Endpoints in Pediatric Cancer Supportive Care: Illustrative Examples From Two Multi‐Center Phase‐III Randomized Clinical Trials

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric supportive care clinical trials often involve multiple clinically important outcomes, complicating trial interpretation. Hierarchical composite endpoints (HCEs) provide a framework to integrate key outcomes according to clinical importance.
Willem H. Collier, Mark Zobeck, Adam J. Esbenshade, Christopher C. Dvorak, Lillian Sung, David Freyer, Sarah Alexander, Etan Orgel, Nicole J. Ullrich, Zach Prudowsky, Brian Fisher, Caitlin W. Elgarten   +11 more
wiley   +1 more source

CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia

Haematologica, 2019
The potential of CD123-targeted therapies in acute lymphoblastic leukemia/lymphoma remains largely unexplored. We examined CD123 expression levels in a large cohort of patients with acute lymphoblastic leukemia/lymphoma and assessed the in vitro impact ...
Evgeniya Angelova, Charlene Audette, Yelena Kovtun, Naval Daver, Sa A. Wang, Sherry Pierce, Sergej N. Konoplev, Haitham Khogeer, Jeffrey L. Jorgensen, Marina Konopleva, Patrick A. Zweidler-McKay, L. Jeffrey Medeiros, Hagop M. Kantarjian, Elias J. Jabbour, Joseph D. Khoury   +14 more
doaj   +1 more source

Poor Prognosis Biomolecular Factors Are Highly Frequent in Childhood Acute Leukemias From Oaxaca, Mexico

Technology in Cancer Research & Treatment, 2020
Objective: To investigate the cellular and molecular epidemiology of acute leukemias in vulnerable populations of children and adolescents in Oaxaca de Juarez, Mexico.
Gerardo Juárez-Avendaño MSc, Nuria Citlalli Luna-Silva MD, Euler Chargoy-Vivaldo MD, Laura Alicia Juárez-Martínez MD, Mayra Noemí Martínez-Rangel BS, Noemí Zárate-Ortiz BS, Edith Martínez-Valencia BS, Briceida López-Martínez MD, Rosana Pelayo PhD, Juan Carlos Balandrán PhD   +9 more
doaj   +1 more source

Determining Parental Factors for Clinical Trial Attrition in Pediatric Acute Lymphoblastic Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background/Objectives Despite high enrollment rates on Children's Oncology Group (COG) protocols, attrition after initial consent is challenging, introducing bias and prolonging trial completion. While adult oncology literature has identified predictors of withdrawal, little is known about caregiver decision‐making for child participation in ...
Kimberly L. Stathas, Jakob Q. Weiss, Kellee N. Parker, Cathy Lee‐Miller   +3 more
wiley   +1 more source

ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia

Haematologica, 2019
Differentiation therapies achieve remarkable success in acute promyelocytic leukemia, a subtype of acute myeloid leukemia. However, excluding acute promyelocytic leukemia, clinical benefits of differentiation therapies are negligible in acute myeloid ...
Jianbiao Zhou, Jessie Yiying Quah, Yvonne Ng, Jing-Yuan Chooi, Sabrina Hui-Min Toh, Baohong Lin, Tuan Zea Tan, Hiroki Hosoi, Motomi Osato, Qihui Seet, A.G. Lisa Ooi, Bertil Lindmark, Mark McHale, Wee-Joo Chng   +13 more
doaj   +1 more source

Administering Blinatumomab via Continuous Intravenous Infusion in Pediatric Patients—A Single‐Institution Retrospective Review

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Blinatumomab, a CD19xCD3 bispecific T‐cell engager, has become standard therapy for children with de novo B‐cell acute lymphoblastic leukemia (B‐ALL). This retrospective review describes the experience of blinatumomab administration in pediatric patients.
Julia M. Hurley, Ryleigh Krueger, Kellie Joyce, James Stanley, Mary Waskerwitz‐Freyer, Marielle Klunder, David J. Hoogstra   +6 more
wiley   +1 more source

Molecular basis for the diagnosis and treatment of acute promyelocytic leukemia

Revista Brasileira de Hematologia e Hemoterapia, 2012
Acute promyelocytic leukemia is characterized by gene rearrangements that always involve the retinoic acid receptor alpha on chromosome 15. In the majority of patients t(15;17) is detected, which generates the promyelocytic leukemia gene/retinoic acid ...
Sarah Cristina Bassi, Eduardo Magalhães Rego   +1 more
doaj   +1 more source

Occurrence of Extramedullary Relapses in Pediatric Acute Lymphoblastic Leukemia After Treatment With Blinatumomab

Pediatric Blood &Cancer, EarlyView.
ABSTRACT We report a retrospective single‐center analysis of pediatric patients with relapsed or refractory B‐cell precursor acute lymphoblastic leukemia focusing on relapses outside of the typical locations, bone marrow, central nervous system, or testes.
Johanna Kunz, Martin Ebinger, Michaela Döring, Markus Mezger, Ursula Holzer, Rupert Handgretinger, Peter Lang, Manon Queudeville   +7 more
wiley   +1 more source